Targeting cancer using fragment based drug discovery.
Anticancer Agents Med Chem
; 12(1): 40-8, 2012 Jan.
Article
en En
| MEDLINE
| ID: mdl-21707503
ABSTRACT
Over the past decade, fragment-based drug discovery has developed significantly and has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening approaches for hit identification. Fragment-based methods are capable of rapidly identifying starting points for structure-based drug design from relatively small libraries of low molecular weight compounds. The main constraints are the need for sensitive methods that can reliably detect the typically weak interactions between fragments and the target protein, and strategies for transforming fragments into higher molecular weight drug candidates. This approach has recently been validated as series of compounds from various programs have entered clinical trials.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Bibliotecas de Moléculas Pequeñas
/
Descubrimiento de Drogas
/
Neoplasias
/
Antineoplásicos
Idioma:
En
Revista:
Anticancer Agents Med Chem
Asunto de la revista:
ANTINEOPLASICOS
/
QUIMICA
Año:
2012
Tipo del documento:
Article